Thursday, October 19, 2017 8:08:30 AM
ONCS - 1.28 Pre-market now at 1.46/1.48
OncoSec Medical Shares Jump 38% Pre-Bell; Melanoma Drug Combo Shows Best Overall Response Rate of 50%
OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
OncoSec Medical Shares Jump 38% Pre-Bell; Melanoma Drug Combo Shows Best Overall Response Rate of 50%
OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
